RS50906B - Primena specifične doze natrijum fondaparinuksa za lečenje acs - Google Patents

Primena specifične doze natrijum fondaparinuksa za lečenje acs

Info

Publication number
RS50906B
RS50906B YUP-267/04A YUP26704A RS50906B RS 50906 B RS50906 B RS 50906B YU P26704 A YUP26704 A YU P26704A RS 50906 B RS50906 B RS 50906B
Authority
RS
Serbia
Prior art keywords
acs
treatment
dose
sulfo
glucopyranosyl
Prior art date
Application number
YUP-267/04A
Other languages
English (en)
Serbian (sr)
Inventor
Anthonie Wilhelmus Arnold Lensing
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50906(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of RS26704A publication Critical patent/RS26704A/sr
Publication of RS50906B publication Critical patent/RS50906B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
YUP-267/04A 2001-11-13 2002-11-07 Primena specifične doze natrijum fondaparinuksa za lečenje acs RS50906B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13
PCT/EP2002/012482 WO2003041722A1 (en) 2001-11-13 2002-11-07 Use of specific dose of fondaparinux sodium for the treatment of acs

Publications (2)

Publication Number Publication Date
RS26704A RS26704A (sr) 2007-02-05
RS50906B true RS50906B (sr) 2010-08-31

Family

ID=8181220

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-267/04A RS50906B (sr) 2001-11-13 2002-11-07 Primena specifične doze natrijum fondaparinuksa za lečenje acs

Country Status (36)

Country Link
US (1) US20040248848A1 (enExample)
EP (1) EP1446131B1 (enExample)
JP (1) JP4523276B2 (enExample)
KR (1) KR20050044318A (enExample)
CN (1) CN1602197A (enExample)
AP (1) AP1820A (enExample)
AR (1) AR037291A1 (enExample)
AT (1) ATE361753T1 (enExample)
AU (1) AU2002351915B2 (enExample)
BR (1) BR0212915A (enExample)
CA (1) CA2465776A1 (enExample)
CO (1) CO5580790A2 (enExample)
CY (1) CY1106765T1 (enExample)
DE (1) DE60220084T2 (enExample)
DK (1) DK1446131T3 (enExample)
EA (1) EA007325B1 (enExample)
EC (1) ECSP045041A (enExample)
ES (1) ES2287343T3 (enExample)
GE (1) GEP20074097B (enExample)
HR (1) HRP20040303B1 (enExample)
HU (1) HU228959B1 (enExample)
IL (2) IL161114A0 (enExample)
IS (1) IS2484B (enExample)
MA (1) MA27071A1 (enExample)
ME (2) ME00229B (enExample)
MX (1) MXPA04003045A (enExample)
NO (1) NO20041320L (enExample)
NZ (1) NZ552129A (enExample)
PE (1) PE20030740A1 (enExample)
PL (1) PL206008B1 (enExample)
PT (1) PT1446131E (enExample)
RS (1) RS50906B (enExample)
SI (1) SI1446131T1 (enExample)
UA (1) UA80399C2 (enExample)
WO (1) WO2003041722A1 (enExample)
ZA (1) ZA200402464B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种磺达肝癸钠注射液组合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
CA2199642C (en) * 1997-03-10 2001-05-08 Roger Cariou Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
JP2006501815A (ja) * 2002-04-25 2006-01-19 モメンタ ファーマシューティカルズ インコーポレイテッド 粘膜送達のための方法および製品

Also Published As

Publication number Publication date
US20040248848A1 (en) 2004-12-09
HU228959B1 (en) 2013-07-29
HRP20040303A2 (en) 2004-10-31
RS26704A (sr) 2007-02-05
AP2004003014A0 (en) 2004-06-30
ATE361753T1 (de) 2007-06-15
NO20041320L (no) 2004-06-14
CY1106765T1 (el) 2012-05-23
MA27071A1 (fr) 2004-12-20
KR20050044318A (ko) 2005-05-12
EA007325B1 (ru) 2006-08-25
HRP20040303B1 (hr) 2012-02-29
AP1820A (en) 2008-01-11
MEP1108A (en) 2011-02-10
ME00229B (me) 2011-10-10
MXPA04003045A (es) 2005-06-20
BR0212915A (pt) 2004-10-13
HUP0401462A2 (en) 2006-02-28
JP4523276B2 (ja) 2010-08-11
HK1070561A1 (en) 2005-06-24
CA2465776A1 (en) 2003-05-22
CO5580790A2 (es) 2005-11-30
PL369027A1 (en) 2005-04-18
IL161114A (en) 2010-11-30
ZA200402464B (en) 2005-06-29
EP1446131B1 (en) 2007-05-09
AU2002351915B2 (en) 2007-11-29
WO2003041722A1 (en) 2003-05-22
CN1602197A (zh) 2005-03-30
DK1446131T3 (da) 2007-09-10
IL161114A0 (en) 2004-08-31
UA80399C2 (en) 2007-09-25
ES2287343T3 (es) 2007-12-16
ECSP045041A (es) 2004-04-28
HUP0401462A3 (en) 2006-04-28
DE60220084T2 (de) 2008-01-10
SI1446131T1 (sl) 2007-10-31
DE60220084D1 (de) 2007-06-21
IS2484B (is) 2008-12-15
JP2005509007A (ja) 2005-04-07
EA200400382A1 (ru) 2004-10-28
NZ552129A (en) 2008-04-30
PL206008B1 (pl) 2010-06-30
EP1446131A1 (en) 2004-08-18
IS7199A (is) 2004-03-29
PE20030740A1 (es) 2003-08-28
PT1446131E (pt) 2007-08-07
AR037291A1 (es) 2004-11-03
GEP20074097B (en) 2007-05-10

Similar Documents

Publication Publication Date Title
Rentrop et al. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial.
Adams et al. The effect of agents which modify platelet behaviour and of magnesium ions on thrombus formation in vivo
Wilson et al. Serious ventricular dysrhythmias after intracoronary papaverine
Weaver et al. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction
US8680052B1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
Jordaens et al. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia
Bär et al. Comparison of saruplase and alteplase in acute myocardial infarction
RS50906B (sr) Primena specifične doze natrijum fondaparinuksa za lečenje acs
AU2002351915A1 (en) Uso of specific dose of fondaparinux sodium for the treatment of ACS
JP2005509007A6 (ja) Ａｃｓの治療のためのフォンダパリヌックスナトリウムの特定投与量の使用
EP2964233B1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
HK1070561B (en) Use of specific dose of fondaparinux sodium for the treatment of acs
ES2262971T3 (es) Idraparinux (sanorg 34006) para el tratamiento y profilaxis secundaria de sucesos tromboembolicos venosos en pacientes con trombosis venosa intensa.
KR20150047515A (ko) 관상동맥 우회로 이식술이 예정된 환자의 st 비상승 급성 관상동맥 증후군 치료에 사용되는 오타믹사반
Serebruany et al. Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor
Taylor Post-ischemic myocardial function
KAPPENBERGER Use of Amiodarone in the Management of the Wolff‐Parkinson‐White Syndrome